[Molecular aspects of prostate cancer: recent data from the literature]
- PMID: 17845997
[Molecular aspects of prostate cancer: recent data from the literature]
Abstract
A meta-analysis of recent data from the literature underscores the considerable body of present knowledge concerning prostate carcinogenesis, in part due to the numerous molecular biology tools now at our disposal. As concerns early events, much interest is being paid to modifications in the expression of GSTP1 and NKX3.1 occurring in totipotent stem cell populations. The discovery of fusion genes implicating TMPRSS2 and ERG (and, on rare occasions, other ETS family transcription factors) constitutes a major advance. Under physiological androgenic stimulation, the presence of these fusion genes leads to overexpression of genes involved in cell growth and differentiation. Concomitantly, alterations in numerous signalling pathways (growth factors, Wnt-beta catenine, PI3K/Akt) are responsible for the onset of an aggressive tumor phenotype. Hormono-independence is currently explained by an amplification of, or mutations in, androgenic receptors. These are facilitated by genomic instabilities linked to alterations in proteins which regulate gene expression, such as EZH2, and by the influence of the tumor microenvironment. Disturbances in the interactions between tumor cells and the microenvironment contribute to local extension of the tumor. Changes in the expression of E-cadherin are responsible for modifications in cell adhesion to the extracellular matrix. The expression of metalloproteases and of angiogenic factors favors tumor dissemination. Finally, the bone tropism in prostate metastases is probably linked to osteomimetic properties of prostate tumor cells which are capable of expressing certain proteins involved in bone remodelling, such as Runx-2, BSP (bone sialoprotein) and BMP (bone morphogenetic protein). Numerous studies remain to be carried out in order to correlate the identified genetic profiles and molecular anomalies with tumor prognosis. Nevertheless, the possibility of decrypting these anomalies for use in therapeutic applications is encouraging.
Similar articles
-
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547. PLoS One. 2010. PMID: 20479932 Free PMC article.
-
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.Cancer Res. 2006 Nov 1;66(21):10242-6. doi: 10.1158/0008-5472.CAN-06-1986. Cancer Res. 2006. PMID: 17079440
-
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.Eur Urol. 2007 Aug;52(2):455-63. doi: 10.1016/j.eururo.2006.11.020. Epub 2006 Nov 17. Eur Urol. 2007. PMID: 17134822
-
Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.Asian J Androl. 2012 May;14(3):436-50. doi: 10.1038/aja.2011.160. Epub 2012 Feb 27. Asian J Androl. 2012. PMID: 22367183 Free PMC article. Review.
-
ETS fusion genes in prostate cancer.Endocr Relat Cancer. 2014 May 6;21(3):R143-52. doi: 10.1530/ERC-13-0390. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24659477 Review.
Cited by
-
Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets.Int J Mol Sci. 2018 Jan 4;19(1):148. doi: 10.3390/ijms19010148. Int J Mol Sci. 2018. PMID: 29300334 Free PMC article. Review.
-
Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.Neoplasia. 2010 Feb;12(2):192-205. doi: 10.1593/neo.91836. Neoplasia. 2010. PMID: 20126477 Free PMC article.
-
Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61. doi: 10.1016/j.urology.2009.01.087. Epub 2009 Aug 3. Urology. 2009. PMID: 19647299 Free PMC article.
-
EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling.Oncotarget. 2016 Jul 19;7(29):45134-45143. doi: 10.18632/oncotarget.9761. Oncotarget. 2016. PMID: 27259264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous